Author

Mary Kate Morris

Primary ORCID profile (0000-0003-0143-5615 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Mary Kate MorrisiD1 paper · California Department of Public Health

Biology Disciplines

Click to filter author papers

Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

Carl Hanson· 1 shared Jonathan Do· 1 shared Mrinmoy SanyaliD· 1 shared Natalia Friedland· 1 shared Payton A.-B. Weidenbacher· 1 shared Peter S. KimiD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Carl Hanson

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

BiochemistrybioRxivPreprintJun 27, 2023

Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern

Payton A.-B. Weidenbacher, Natalia Friedland, Mrinmoy Sanyal…·Peter S. Kim

This study evaluates the efficacy of a pan-sarbecovirus vaccine candidate against SARS-CoV-2 variants, finding that omitting strain-specific mutations improves cross-reactive neutralizing antibody responses.

DOI 10.1101/2023.06.27.546764

non-human primateproteomics

𝕏 PostBluesky